Vanessa Waddell

PolyActiva Secures $40M in Series C Financing to Advance Innovation in Sustained Ocular Drug Delivery

Australian biotech PolyActiva has raised A$40 million in Series C funding to advance its PA5108 ocular implant and PREZIA platform, backed by the National Reconstruction Fund Corporation and Brandon Capital.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·SmartCompany·polyactiva.com·Startup Daily·ophthalmologybreakingnews.com·Forbes Australia

NRF backs PolyActiva in $40 million raise for dissolvable eye implants

Biotech PolyActiva has banked a Series C round led by the National Reconstruction Fund with Brandon Capital, funding late-stage trials of its dissolvable glaucoma implant and a consolidated Melbourne site.

Also Startup Daily

PolyActiva Showcases Promising Clinical Data Highlighting its Polymer Technology's Potential to Transform Glaucoma Care

PolyActiva reported Phase 2 results showing its PA5108 ocular implant lowered eye pressure safely in glaucoma patients, with a phase 2b trial planned, after presentations at two ophthalmology conferences.